The market is up, but it’s all theatre: Don’t let The Fed’s buying suck you in

Chris Parry
March 24, 2020
Trust me, there’s nothing I’d like more, as the publisher of a financial markets-focused media outlet, than to tell you all it’s time to buy back in on these ailing markets. I’ve got clients who’d reward me well if I were to convince you that it’d be a good idea to buy their stock in the middle of a stock slide. I’ve got employees that I’m still paying and not laying off that are ready to do their thing and share good investing opportunities with you all, especially at a time when you’re all at home looking for information.

Shroom stocks go nuts: First movers SHRM, MMED, RVV up hard as gamblers gamble

Chris Parry
March 4, 2020
Today was a day that daytraders have been looking forward to for some time; the day that shroom stocks finally gripped the road and took off. Mind Medicine (MMED.E) ripped 90% to $0.77 on the back of 15m shares traded, reminding anyone who'd listen that ex-Canopy CEO Bruce Linton and pretend billionaire Kevin O'Leary were on board. Champignon Brands (SHRM.C) zoomed 40% to $0.33 on a lot smaller market awareness spend byt a handy ticker, Roadman Investments (LITT.V) was up 30% to $0.065 being sucked along in the other two companies' wake, and Revive Therapeutics (RVV.C) was up 81% to $0.10 on ripples caused by the rest.